|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0169 USD | +0.93% |
|
0.00% | +3.68% |
| 05-27 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 8.21M 5.79M 5M 4.61M 4.32M 8.09M 551M 54.43M 21.22M 268M 21.74M 21.28M 928M | P/E Ratio 2024 |
-3.44x | P/E Ratio 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 10.98M 7.75M 6.69M 6.17M 5.77M 10.82M 736M 72.81M 28.39M 358M 29.08M 28.46M 1.24B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 22-05-22 | Acrux : Application for quotation of securities - ACR | PU |
| 22-04-13 | Acrux : Application for quotation of securities - ACR | PU |
| 22-03-15 | Acrux : Application for quotation of securities - ACR | PU |
| 22-02-24 | Acrux : Updated Board Charter | PU |
| 22-02-24 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +0.93% | ||
| Current month | +1.20% | ||
| 1 month | -2.31% | ||
| 3 months | +275.56% | ||
| 6 months | +81.72% | ||
| Current year | +3.68% |
| 1 month | 0.02 | 0.02 | |
| Current year | 0 | 0.02 | |
| 1 year | 0 | 0.05 | |
| 3 years | 0 | 0.06 | |
| 5 years | 0 | 0.1 | |
| 10 years | 0 | 0.28 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 2025-05-31 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 2021-06-20 |
| Chief Tech/Sci/R&D Officer | - | 2015-02-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 2005-12-31 |
Timothy Oldham
BRD | Director/Board Member | - | 2013-09-30 |
Geoff Brooke
BRD | Director/Board Member | 70 | 2016-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.93% | 0.00% | - | - | 6.15M | ||
| -0.09% | +0.96% | +7.16% | +82.72% | 45.63B | ||
| +0.29% | -3.03% | +41.83% | +84.69% | 33.53B | ||
| -0.58% | -0.48% | -9.54% | +38.38% | 11.81B | ||
| -1.50% | +0.05% | +11.67% | +98.14% | 11.69B | ||
| +3.89% | +0.78% | +36.70% | +129.46% | 9.12B | ||
| +0.92% | -0.82% | +19.92% | +43.68% | 7.16B | ||
| +2.37% | +0.76% | +45.05% | -15.33% | 6.49B | ||
| -0.79% | -0.91% | +28.11% | +235.68% | 6.45B | ||
| +0.51% | -3.04% | -43.06% | -3.48% | 5.16B | ||
| Average | +0.59% | -0.07% | +15.32% | +77.10% | 15.23B | |
| Weighted average by Cap. | +0.26% | -0.30% | +18.11% | +81.08% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.59M 3.1M 2.86M 2.68M 5.01M 341M 33.75M 13.16M 166M 13.48M 13.19M 575M | 1.19M 839K 725K 668K 625K 1.17M 79.78M 7.89M 3.08M 38.83M 3.15M 3.08M 134M |
| Net income | -5.8M -4.09M -3.53M -3.26M -3.05M -5.71M -389M -38.44M -14.99M -189M -15.35M -15.03M -655M | -5.94M -4.19M -3.62M -3.34M -3.12M -5.85M -399M -39.41M -15.36M -194M -15.74M -15.4M -672M |
| Net Debt | 759K 535K 462K 426K 399K 747K 50.88M 5.03M 1.96M 24.77M 2.01M 1.97M 85.76M | 2.77M 1.96M 1.69M 1.56M 1.46M 2.73M 186M 18.37M 7.16M 90.45M 7.34M 7.18M 313M |
Employees
43
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
- ARUX.F Stock
Select your edition
All financial news and data tailored to specific country editions
















